Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain

TEL AVIV, Israel, March 20, 2018 -- (Healthcare Sales & Marketing Network) -- Therapix Biosciences Ltd. (NASDAQ: TRPX) ("Therapix" or the "Company"), a biopharmaceutical company focused on discovering, developing, and commercializing n... Biopharmaceuticals, FDA Therapix Biosciences, cannabinoid, THX-110, Low Back Pain
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news